Preliminary efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy for advanced temporal bone squamous cell carcinoma
10.3760/cma.j.cn115330-20250119-00059
- VernacularTitle:帕博利珠单抗联合化疗新辅助治疗晚期颞骨鳞状细胞癌的初步疗效与安全性
- Author:
Yu SI
1
;
Yan HUANG
;
Dian LIU
;
Maojin LIANG
;
Wenting DENG
;
Yuexin CAI
;
Yuebo CHEN
;
Yanfang YE
;
Li LING
;
Zhigang ZHANG
;
Suijun CHEN
Author Information
1. 中山大学孙逸仙纪念医院耳鼻咽喉科 中山大学听力与言语研究所，广州 510030
- Publication Type:Journal Article
- Keywords:
Carcinoma, squamous cell;
Temporal bone;
Neoadjuvant therapy;
Immunotherapy;
Objective response rate;
Pembrolizumab
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2025;60(11):1399-1406
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety of neoadjuvant therapy with pembrolizumab combined with 5-fluorouracil (5-FU) and cisplatin in patients with advanced temporal bone squamous cell carcinoma (TBSCC), and its impact on tumor response rate and disease-free survival (DFS).Methods:This prospective, single-arm, open-label clinical study enrolled patients with advanced (Stage Ⅲ/Ⅳ) TBSCC from Sun Yat-sen Memorial Hospital. Patients received 2-3 cycles of neoadjuvant therapy with pembrolizumab, 5-FU, and cisplatin, followed by definitive surgery. Postoperatively, patients received 6 cycles of pembrolizumab combined with radiotherapy. The primary endpoint was the 2-year disease-free survival (DFS) rate. Secondary endpoints included objective response rate (ORR) and safety indicators. Survival analysis was performed using the Kaplan-Meier method. Adverse events (AE) were assessed using the National Cancer Institute′s Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Statistical analyses were conducted using SPSS software, version 22.0.Results:From August 2021 to April 2024, 16 patients with advanced TBSCC were enrolled (13 males and 3 females), with a median age of 54 years and a median follow-up time of 2.32 years. Following neoadjuvant therapy, the objective response rate (ORR) was 64.3% (9/14), and the disease control rate (DCR) was 92.9% (13/14). The 2-year DFS rate was 86.6%. Common treatment-related adverse events (TRAE) included leukopenia (56.3%, 9/16), nausea and vomiting (50.0%, 8/16), diarrhea, oral mucositis, and elevated liver function tests (25.0%, 4/16). One patient (6.25%) experienced a grade 3 adverse event.Conclusion:Neoadjuvant pembrolizumab-chemotherapy significantly enhances objective response rate and disease-free survival in advanced TBSCC.
